Virginia Patent of the Month – March 2023

Landos Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease.

The company has recently patented a breakthrough in medical treatments for diseases and disorders. Their latest invention targets the Lanthionine C-like protein 2 (LANCL2) signaling pathway to treat and prevent autoimmune, inflammatory, and metabolic conditions, including but not limited to, rheumatoid arthritis, psoriasis, multiple sclerosis, type 2 diabetes, and obesity-related inflammation.

The LANCL2 pathway has been shown to increase insulin sensitivity and reduce inflammation associated with various autoimmune, inflammatory, and metabolic conditions. The company’s compounds targeting this pathway reduce glucose levels and gut inflammation significantly, with a corresponding 4x reduction in the number of lesions in mice. The unique mode of action of the LANCL2 pathway allows for orally administered therapeutics that are as effective as anti-TNF antibodies but without side effects and high cost.

There is has been a noted global rise in autoimmune disorders, including inflammatory bowel disease (IBD), systemic lupus, rheumatoid arthritis, type 1 diabetes, psoriasis, and multiple sclerosis, and a pandemic of chronic metabolic inflammatory diseases including metabolic syndrome, obesity, prediabetes, cardiovascular disease, and type 2 diabetes. Current treatments are moderately effective, but they are expensive and have serious side effects.

Landos Biopharma’s novel ligands of the LANCL2 pathway could allow treatments to be tailored specifically to individual diseases and potentially maximize their efficacy. They have developed a series of classes of compounds using novel medicinal chemistry approaches, which have been screened using in silico, in vitro, and in vivo techniques to maximize their ability to bind to the LANCL2 protein and effect a beneficial response in various disease conditions.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts